Guilin Sanjin Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 14.80%

Guilin Sanjin Pharmaceutical Co Ltd (002275) has an Asset Resilience Ratio of 14.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Guilin Sanjin Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥636.30 Million
≈ $93.11 Million USD Cash + Short-term Investments

Total Assets

CN¥4.30 Billion
≈ $629.19 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2010–2024)

This chart shows how Guilin Sanjin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Guilin Sanjin Pharmaceutical Co Ltd (002275) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Guilin Sanjin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guilin Sanjin Pharmaceutical Co Ltd market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥636.30 Million 14.8%
Total Liquid Assets CN¥636.30 Million 14.80%

Asset Resilience Insights

  • Moderate Liquidity: Guilin Sanjin Pharmaceutical Co Ltd has 14.80% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Guilin Sanjin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guilin Sanjin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Drug Manufacturers - Specialty & Generic 43.05%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 1.96%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Guobang Pharma Ltd
SHG:605507
Drug Manufacturers - Specialty & Generic 8.47%

Annual Asset Resilience Ratio for Guilin Sanjin Pharmaceutical Co Ltd (2010–2024)

The table below shows the annual Asset Resilience Ratio data for Guilin Sanjin Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 14.79% CN¥626.15 Million
≈ $91.62 Million
CN¥4.23 Billion
≈ $619.31 Million
+7.05pp
2023-12-31 7.74% CN¥304.69 Million
≈ $44.59 Million
CN¥3.94 Billion
≈ $575.97 Million
+3.67pp
2022-12-31 4.07% CN¥161.24 Million
≈ $23.59 Million
CN¥3.96 Billion
≈ $580.19 Million
-1.35pp
2021-12-31 5.41% CN¥221.77 Million
≈ $32.45 Million
CN¥4.10 Billion
≈ $599.35 Million
-3.74pp
2020-12-31 9.15% CN¥355.34 Million
≈ $52.00 Million
CN¥3.88 Billion
≈ $568.10 Million
+7.18pp
2019-12-31 1.98% CN¥67.50 Million
≈ $9.88 Million
CN¥3.42 Billion
≈ $499.81 Million
+1.98pp
2018-12-31 0.00% CN¥1.27K
≈ $186.02
CN¥3.41 Billion
≈ $498.42 Million
-11.29pp
2017-12-31 11.29% CN¥364.60 Million
≈ $53.35 Million
CN¥3.23 Billion
≈ $472.59 Million
+3.95pp
2016-12-31 7.34% CN¥210.66 Million
≈ $30.83 Million
CN¥2.87 Billion
≈ $419.95 Million
+3.51pp
2015-12-31 3.83% CN¥105.60 Million
≈ $15.45 Million
CN¥2.76 Billion
≈ $403.83 Million
-5.15pp
2014-12-31 8.98% CN¥250.00 Million
≈ $36.58 Million
CN¥2.78 Billion
≈ $407.33 Million
+8.80pp
2010-12-31 0.18% CN¥3.60 Million
≈ $527.15K
CN¥1.98 Billion
≈ $289.92 Million
--
pp = percentage points

About Guilin Sanjin Pharmaceutical Co Ltd

SHE:002275 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.23 Billion
CN¥8.41 Billion CNY
Market Cap Rank
#8231 Global
#2091 in China
Share Price
CN¥14.31
Change (1 day)
+0.56%
52-Week Range
CN¥13.35 - CN¥17.38
All Time High
CN¥19.61
About

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache … Read more